DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes

Sang Ah Lee
September 2013
Journal of Korean Diabetes;2013, Vol. 14 Issue 3, p128
Academic Journal
Dipeptidylpeptidase-4 (DPP-4) inhibitors are new glucose-lowering agents with mechanisms that differ from those of previous oral hypoglycemic agents (OHAs). DPP-4 inhibitors have shown a continuous glucose lowering effect (> 0.5%) when used in monotherapy as well as when used in combination with metformin, sulfonylurea, thiazolidinedione (TZD), insulin, and any other drug. In addition to improving glucose control, DPP-4 inhibitors have also shown a neutral effect on weight gain, improved β-cell function, and lowered the risk of hypoglycemia. Because of these advantages, DPP-4 inhibitors are widely used in the treatment of all patients with type 2 diabetes mellitus, but especially elderly patients. Therefore, more information regarding these strengths of DPP-4 inhibitors will lead to better treatment of patients with T2DM.


Related Articles

  • Teneligliptin: A Review in Type 2 Diabetes. Scott, Lesley // Clinical Drug Investigation;Nov2015, Vol. 35 Issue 11, p765 

    Oral teneligliptin [Teneglucon (Argentina)], a dipeptidyl peptidase-4 inhibitor, is indicated for the treatment of adults with type 2 diabetes (T2DM). This article reviews the pharmacology, therapeutic efficacy and tolerability of teneligliptin in the treatment of adults with T2DM. In 12- or...

  • Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors. Omar, Bilal; Ahrén, Bo // Diabetes;Jul2014, Vol. 63 Issue 7, p2196 

    Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-lowering treatment for type 2 diabetes. The classical mechanism for DPP-4 inhibitors is that they inhibit DPP-4 activity in peripheral plasma, which prevents the inactivation of the incretin hormone glucagon-like peptide (GLP)-1 in the...

  • Metformin Associated with Less Need for a Second Medicine. SHAUGHNESSY, ALLEN F. // American Family Physician;2/15/2015, Vol. 91 Issue 4, p261 

    The article discusses a study which investigated the initial treatment of type 2 diabetes using oral hypoglycemics other than metformin. Topics discussed include possible cardiovascular event in patients that initially took a sulfonylurea, higher cost of treatment associated with...

  • Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. SOLIS-HERRERA, CAROLINA; TRIPLITT, CURTIS; DE JESÚS GARDUNO-GARCIA, JOSE; ADAMS, JOHN; DEFRONZO, RALPH A.; CERSOSIMO, EUGENIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2756 

    OBJECTIVE--To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS--We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects...

  • Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Shuo-Ming Ou; Chia-Jen Shih; Pei-Wen Chao; Hsi Chu; Shu-Chen Kuo; Yi-Jung Lee; Shuu-Jiun Wang; Chih-Yu Yang; Chih-Ching Lin; Tzeng-Ji Chen; Der-Cherng Tarng; Szu-Yuan Li; Yung-Tai Chen; Ou, Shuo-Ming; Shih, Chia-Jen; Chao, Pei-Wen; Chu, Hsi; Kuo, Shu-Chen; Lee, Yi-Jung; Wang, Shuu-Jiun // Annals of Internal Medicine;11/3/2015, Vol. 163 Issue 9, p663 

    Background: Recent studies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycemic control but also raised concerns about the risk for heart failure in patients with type 2 diabetes mellitus (T2DM). However, large-scale studies of the effects on cardiovascular...

  • Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Hiroyuki Konya; Yuzo Yano; Satoshi Matsutani; Taku Tsunoda; Takashi Ikawa; Yoshiki Kusunoki; Toshihiro Matsuo; Masayuki Miuchi; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-ichiro Miyagawa; Mitsuyoshi Namba // Therapeutics & Clinical Risk Management;2014, Vol. 10, p547 

    Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mel-litus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients...

  • Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Sung-Ho Kim; Jung-Hwa Yoo; Woo Je Lee; Cheol-Young Park // Diabetes & Metabolism Journal;Oct2016, Vol. 40 Issue 5, p339 

    Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing...

  • Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Ahrén, Bo; Foley, James E.; Ferrannini, Ele; Matthews, David R.; Zinman, Bernard; Dejager, Sylvie; Fonseca, Vivian A. // Diabetes Care;Apr2010, Vol. 33 Issue 4, p730 

    OBJECTIVE -- To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. RESEARCH DESIGN AND METHODS -- Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8...

  • Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study. Hassoun, Ahmed A. K.; Pathan, Md Faruque; Medlej, Rita C.; Alarouj, Monira; Shaltout, Inass; Chawla, Manoj S.; Knap, Ditte; Vaz, Julius A. // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Jul2016, Vol. 9, p225 

    Background: VIRTUE was a prospective, observational study assessing the effectiveness and safety of vildagliptin vs sulfonylureas (SUs) (both as monotherapy and in combination with metformin) in patients with type 2 diabetes mellitus who fasted during Ramadan. A post hoc analysis was carried out...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics